Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer
Teva ”) announced today the pricing and early acceptance results of its previously announced tender offers (the “ Offers ”) to purchase for cash the outstanding notes issued by finance subsidiaries of Teva and guaranteed by Teva of the series described in the table below (the “ Notes ”) upon the terms of, and subject to the conditions as set out in, the Offer to Purchase, dated May 19, 2025 (the “ Offer to Purchase ”). Capitalized terms used in this announcement but not otherwise defined...
Nasdaq GlobeNewswire
03/06/2025
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial…
Attachments Notification of managers' transaction - Anthony Rosenberg - May 2025 RSU vestNotification of managers' transaction - Arshad Khanani - May 2025 RSU vest
Nasdaq GlobeNewswire
03/06/2025
U.S. FDA approves third indication of darolutamide for patients with advanced…
ORION CORPORATIONPRESS RELEASE3 JUNE 2025 at 23.30 EEST U.S. FDA approves third indication of darolutamide for patients with advanced prostate cancer Darolutamide is the first and only in the U.S. and FDA-approved androgen receptor inhibitor (ARi) for the treatment of patients with hormone-sensitive prostate cancer (mHSPC), in combination with androgen deprivation therapy (ADT), with or without chemotherapy.This third approval is based on positive results from the...
Nasdaq GlobeNewswire
03/06/2025
DBV Technologies announces the filing of an addendum to the 2024 Universal…
DBV Technologies announces the filing of an addendum to the 2024 Universal Registration DocumentDBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “ Company ”), today announced today the filing of an addendum to the 2024 Universal Registration Document (the “ Addendum ”) with the French market authority, “Autorité des Marchés Financiers” (“ AMF ”).This Addendum provides an update to the Board of Directors'...
Nasdaq GlobeNewswire
03/06/2025
EssilorLuxottica: successful Euro 1 billion bond issuance
NOT TO BE RELEASED, PUBLISHED OR DISTRIBUTED DIRECTLY OR INDIRECTLY IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR IN ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS PRESS RELEASE This press release does not constitute a solicitation nor an offer to purchase the Bonds (as such term is defined below) in the United States of America or to, or for the account or benefit of, U.S. Persons (as defined in Regulation S under the US...
Nasdaq GlobeNewswire
03/06/2025
Camurus and Lilly enter collaboration and license agreement for long-acting…
In return for granting Lilly the license to use the FluidCrystal technology for the selected incretin drug compounds for cardiometabolic health, Camurus is eligible to receive up to $290 million in upfront, development, and regulatory milestone payments as well as $580 million in sales-based milestone payments and tiered mid-single digit royalties on global net product sales. In return for granting Lilly the license to use the FluidCrystal technology for the selected incretin drug compounds…
PR Newswire
03/06/2025
EssilorLuxottica: Result of the payment of dividends in shares and record of the…
Result of the payment of dividends in shares and record of the corresponding capital increaseParis, France(June 3, 2025 – 4:30 pm)– The Annual General Meeting of EssilorLuxottica has decided to grant to the shareholders the option to receive their dividend in shares. The price for newly issued shares for the payment of the dividend has been set at Euro 222.02 per share. This price corresponds to 90% of the average of the opening prices quoted on Euronext Paris over the twenty...
Nasdaq GlobeNewswire
03/06/2025
Digital Pathology Market worth US$2.75 billion by 2030 with 13.5% CAGR |…
As digital pathology becomes more widely adopted, healthcare organizations are increasingly drawing insights from early implementers to guide their own strategies. However, the market still faces challenges such as a shortage of trained pathologists, high initial investment requirements, and uncertainty around reimbursement policies, which may hinder widespread deployment in some regions. As digital pathology becomes more widely adopted, healthcare organizations are increasingly drawing...
PR Newswire
03/06/2025
Medical Writing Market Size to Grow at 10.46% CAGR, Globally, by 2030 -…
For More Information and To Stay Updated on The Latest Developments in The Medical Writing Market Size, Download FREE Sample Pages: https://www.theresearchinsights.com/request_sample?id=10439 For More Information and To Stay Updated on The Latest Developments in The Medical Writing Market Size, Download FREE Sample Pages: https://www.theresearchinsights.com/request_sample?id=10439 Market Overview and Growth Trajectory: Medical Writing Market Growth: According to an exhaustive...
PR Newswire
03/06/2025
Mintel Acquires Black Swan Data, revolutionising predictive intelligence and…
"Mintel's acquisition of Black Swan Data unites our strengths in structured data, advanced technology, human expertise, and real-time social analytics to deliver unparalleled predictive intelligence for our clients," said Matt Nelson, Mintel CEO. "Our immediate goal is to transform front-end innovation, delivering the clarity CPG brands need to understand where to play, what to prioritise, and how to win with greater precision and confidence." "Mintel's acquisition of…
PR Newswire
03/06/2025
3i Announces Launch of the G10+: World's First Robot Vacuum with Debris…
Low-Noise Debris Compression, 60 Days Without Emptying Low-Noise Debris Compression, 60 Days Without Emptying What powers the G10+ is 3i's patented debris compression technology. A mechanical paddle actively compresses dust and debris in real time, allowing the robot to store up to 60 days' worth of waste in its extra-large 1000ml dustbin, completely hands-free. To ensure hygiene, the G10+ features a built-in UV light that disinfects the stored debris, offering users added peace of…
PR Newswire
03/06/2025
Evaxion receives grant funding to design new polio vaccine
Evaxion awarded a grant from the Gates FoundationGrant funds research aimed at ultimately eradicating polio, a highly infectious viral diseaseEvaxion will apply its leading AI-Immunology™ platform to identify and combine various antigens to combat the virus and develop design options for a potential new vaccine constructRisk of a global polio resurgence and health crisis remain, thus a new vaccine concept is warrantedCOPENHAGEN, Denmark, June 3, 2025 - Evaxion A/S (NASDAQ:...
Nasdaq GlobeNewswire
03/06/2025
Press Release: ASCO: new Sarclisa data support subcutaneous administration with…
ASCO: new Sarclisa data support subcutaneous administration with on-body injector New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety compared to intravenous infusionStudies used Enable Injections' enFuse ®on-body injector, an automated hands-free injectorData will form the basis of global regulatory submissions across all currently...
Nasdaq GlobeNewswire
03/06/2025
Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender…
Teva ”) announced today the early tender results in connection with its previously announced tender offers (the “ Offers ”) as specified below for the following series of notes issued by finance subsidiaries of Teva and guaranteed by Teva: USD 3.150% Senior Notes due 2026, CUSIP 88167AAE1 / ISIN US88167AAE10 (Registered), issued by Teva Pharmaceutical Finance Netherlands III B.V. (the “ Pool 1 Notes ”);USD 4.750% Sustainability-Linked Senior Notes due 2027, CUSIP 88167AAP6 / ISIN...
Nasdaq GlobeNewswire
03/06/2025
Coloplast A/S - Invitation to Coloplast's Capital Markets Day on 2 September…
The event will take place onTuesday, 2 September 2025 at Clarion Hotel (Copenhagen airport) Ellehammersvej 20, 2770 Kastrup from 10.30 - 17.00 CEST(Central European Summer Time)Coloplast invites institutional investors, equity analysts and media to attend our 2025 Capital Markets Day. The event will be held in person at Clarion Hotel in Copenhagen, Denmark, with the option to join virtually for the plenary session. The purpose of the event is to give institutional investors and...
Nasdaq GlobeNewswire
03/06/2025
Invitation: Sobi's Aspaveli® - 52-week Phase 3 VALIANT data in nephrology
The presentation can be followed live here or afterwards on sobi.com. The slides will be made available on sobi.com before the conference call. The presentation can be followed livehere or afterwards on sobi.com. The slides will be made available onsobi.com before the conference call. To participate in the conference call, please use the following dial-in details: Sweden : +46 8 5051 0031United Kingdom : +44 207 107 06 13United States : +1 631 570 56 13 For other countries,...
PR Newswire
03/06/2025
Sixth Global Pharma Company Selects LifeSphere NavaX for GenAI-Driven Case…
The company currently processes over 150,000 adverse event cases annually using the LifeSphere MultiVigilance platform. By leveraging NavaX, which includes dynamic data extraction and narrative generation capabilities, the organization will drive up to 65% efficiency gains across case processing while ensuring 90% data accuracy in intake. The NavaX implementation is set to go live in a few short months, in the fall of 2025. The company currently processes over 150,000 adverse event cases...
PR Newswire
03/06/2025
Asgard Therapeutics strengthens its Board of Directors and Advisory Board with…
With decades of experience in global drug development, new company formation, value creation and strategic guidance, Dr Cristina Csimma brings significant expertise in venture capital and the US biotech capital market to Asgard's Board of Directors. Cristina also holds board director positions at Syncona Limited (a FTSE 250 company), and New York Blood Center Ventures. With decades of experience in global drug development, new company formation, value creation and strategic guidance,Dr...
PR Newswire
03/06/2025
Oculis to Participate in Upcoming June Investor Conferences
/ ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis will be participating in the following upcoming investor conferences: Goldman Sachs Annual Healthcare ConferenceJune 9-11; Miami, FL, U.S. Fireside chat with Riad Sherif, MD, Chief Executive Officer, on June 10th from 9:20 to 9:55am ET.J.P. Morgan European Healthcare Conference June...
Nasdaq GlobeNewswire
03/06/2025
Amber Implants Announces Successful One-Year Follow-Up Data in First-in-Human…
Notably, no device-related adverse events were reported in any patient at the one-year follow-up, underscoring the strong safety profile and promising clinical potential of VCFix®. In addition, significant improvements in key clinical performance outcomes were observed, regardless of cement augmentation. Patients, both with and without cement, experienced immediate and sustained reductions in pain levels, as assessed by the Numeric Pain Rating Scale (NPRS). By the 6-month follow-up, pain scores…
PR Newswire
03/06/2025
Maxim Group initiates the coverage of the CROSSJECT share with a BUY…
Press releaseMaxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of €4.00Dijon, France 03 June 2025 (07.30 CET) -- CROSSJECT(ISIN: FR0011716265; Euronext: ALCJ), the specialty pharma company in advanced phases of development and registration for ZEPIZURE® in adults, is informing about the recent initiation of coverage by Maxim Group, the US brokerage firm dedicated to biopharmaceutical companies and other emerging growth and...
Nasdaq GlobeNewswire
03/06/2025
Addex Convenes Annual General Meeting 2025
Geneva, Switzerland, June 3, 2025- Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its 2025 Annual General Meeting will take place on Tuesday June 24, 2025, at 11:00 am CEST at the Campus Biotech, Chemin des Mines 9, 1202 Geneva (doors open at 10:30 am). Agenda 1. Approval of the Annual Report, the Annual...
Nasdaq GlobeNewswire
03/06/2025
Roche's Tecentriq combined with lurbinectedin shows significant survival benefit…
46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with limited survival and few treatment options 1 First Phase III study in ES-SCLC first-line maintenance to demonstrate clinically meaningful improvements in both progression-free and overall survival 2,3 Data were presented in an oral session at the 2025 ASCO Annual Meeting and simultaneously published inThe Lancet1,4 Basel, 3 June 2025...
Nasdaq GlobeNewswire
03/06/2025
Press Release: Rilzabrutinib granted orphan drug designation in the US for…
Rilzabrutinib granted orphan drug designation in the US for sickle cell diseaseFourth orphan drug designation for rilzabrutinib in rare diseasesUnder regulatory review in the US, the EU, and China in immune thrombocytopeniaParis, June 3, 2025. The US Food and Drug Administration (FDA) has granted orphan drug designation to rilzabrutinib, a novel, advanced, oral, reversible Bruton's tyrosine kinase (BTK) inhibitor that works via multi-immune modulation, to target a reduction in...
Nasdaq GlobeNewswire
03/06/2025
Altri Comunicati
